NCT07111832View on ClinicalTrials.gov

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

December 31, 2028

Conditions
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Interventions
DRUG

SHR-A1811 for Injection

SHR-A1811 for injection.

DRUG

SHR-1316 Injection

SHR-1316 injection.

DRUG

Toripalimab Injection

Toripalimab injection.

DRUG

Paclitaxel for Injection

Paclitaxel for injection.

Trial Locations (2)

100142

Peking University Cancer Hospital, Beijing

200032

Cancer Hospital，Fudan University, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY